Live Breaking News & Updates on Alexandria Forbes

Stay updated with breaking news from Alexandria forbes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress

LONDON and NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therap. ....

Bruxelles Capitale , City Of , United Kingdom , Jason Braco , European Society Of Gene , Meiragtx Holdings , Lifesci Communications , European Society , Cell Therapy , Alexandria Forbes , Preclinical Efficacy , Gene Therapy , Sensory Disease , Xerostomia Specific Questionnaire , Global Rate , Change Questionnaire , Adeno Associated Virus , Human Embryonic Kidney , Good Manufacturing Practice Compatible , Central Composite Design , Host Cell Proteins , Private Securities Litigation Reform Act , Quarterly Report ,

MeiraGTx Reports Second Quarter 2023 Financial and Operational Results

Phase 3 LUMEOS clinical trial of botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) enrollment target has now been surpassedAnnounced positive clinical data from the completed AQUAx Phase 1 study of AAV2-hAQP1 for the treatment of grade 2/3 radiation-induced xerostomia (RIX), showing bilaterally treated participants reaching normal levels of whole saliva flow rate by 2 months post-treatment and persisting through the final Month 12 ....

City Of , United Kingdom , United States , Jason Braco , Association For Research , Lifesci Communications , American Society Of Gene , Meiragtx Holdings , Cell Therapy , Alexandria Forbes , Development Highlights , Anticipated Milestones , Induced Xerostomia , Owned Gene Therapy Manufacturing Facility , Received Commercial , Gene Regulation Platform , Vector Engineering , Private Securities Litigation Reform Act , Quarterly Report , Six Month Period Ended June , Gene Regulation , Gene Therapy , Clinical Programs , Clinical Stage , Clinical Trials ,

MeiraGTx Announces Poster Presentation at the 2023 American

RiboCAR-T cell activity can be precisely tuned and “remotely” controlled to improve the efficacy, durability and safety of CAR-T cell therapy. ....

United States , City Of , United Kingdom , Jason Braco , Lifesci Communications , American Society Of Gene , Meiragtx Holdings , Exchange Commission , Cell Therapy , Alexandria Forbes , Riboswitch Regulated Chimeric Antigen Receptor , Private Securities Litigation Reform Act , Nasdaq Mgtx ,

MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology

RiboCAR-T cell activity can be precisely tuned and “remotely” controlled to improve the efficacy, durability and safety of CAR-T cell therapyLONDON and NEW YORK, Aug. 01, 2023 MeiraGTx. ....

City Of , United Kingdom , United States , Jason Braco , Lifesci Communications , American Society Of Gene , Exchange Commission , Meiragtx Holdings , Cell Therapy , Alexandria Forbes , Riboswitch Regulated Chimeric Antigen Receptor , Private Securities Litigation Reform Act ,

MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has ...

LONDON and NEW YORK, July 19, 2023 (GLOBE NEWSWIRE) MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that after a successful inspection ....

City Of , United Kingdom , Jason Braco , Irish Health Products Regulatory Authority , Exchange Commission , Lifesci Communications , Meiragtx Holdings , Commercial Manufacturer , Quality Control , Alexandria Forbes , Private Securities Litigation Reform Act ,